Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CoImmune","sponsor":"FIDIM Group","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"CoImmune Announces Closing of $45 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CoImmune","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by CoImmune

    Menu

    CoImmune

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              CoImmune

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020

              Details:

              ITI will employ CoImmune’s process for manufacturing and cGMP work for the advancement of ITI-1020, ITI’s autologous dendritic cell (DC) investigational vaccine loading with mRNA encoding LAMP: pp65 for the treatment of newly diagnosed glioblastoma (GBM).

              Lead Product(s): ITI-1020

              Therapeutic Area: Oncology Product Name: ITI-1020

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Immunomic Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CoImmune

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CoImmune Announces Closing of $45 Million Series A Financing

              Details:

              CoImmune will use the proceeds from the financing to fund its ongoing Phase 2b trial for lead asset, CMN-001, in advanced renal cell carcinoma and multiple Phase 1-2a trials with its newly acquired technology, CAR-CIK, in five leukemia and lymphoma settings.

              Lead Product(s): CMN-001

              Therapeutic Area: Oncology Product Name: CMN-001

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: FIDIM Group

              Deal Size: $45.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing November 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY